Physician profile
Gabriel E Mena
NPI 1205920030
$494,144.60
in general payments reported to CMS, 2019-2025
12 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233K · 2020: $196K · 2021: $39K · 2022: $636 · 2023: $1,289 · 2024: $3,554 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,125.00 |
| Food and Beverage | $1,958.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $468,528.94 | 2019-2023 | Iovera, Zilretta, Exparel |
| Conmed Corporation | $12,376.07 | 2023-2025 | Airseal |
| Atricure, INC. | $11,571.61 | 2023-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Biotronik INC. | $407.84 | 2019-2021 | |
| Mindray Ds USA, INC. | $338.15 | 2022-2023 | A7 Anesthesia System |
| Heron Therapeutics, INC. | $272.74 | 2020-2023 | Aponvie, Zynrelef |
| Medtronic, INC. | $168.34 | 2022 | |
| Abbott Laboratories | $162.12 | 2023 | Confirm Rx |
| Eagle Pharmaceuticals, INC. | $124.98 | 2023 | |
| Bard Peripheral Vascular, INC. | $111.11 | 2023 | Venclose Maven Catheter |
| On Target Laboratories, INC | $64.08 | 2025 | Cytalux |
| Medline Industries Lp | $18.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Mena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.